Fight, fight, fight against the dying of the light. Evolution never selected for longer lives, it only selected for passing along our genes. Screw evolution. It’s time to take matters into our own hands and extend our healthspan. -- Peter Diamandis
Review: aggressive LDL lowering outweighs theoretical risks, yet few reach <55 mg/dL
Summarises a July 2025 review: guidelines now target LDL-C <55 mg/dL (<40 after a recurrent event), PCSK9 inhibitors add 59-62% LDL reduction, and evidence (FOURIER, CTT meta-analysis, PCSK9 genetics) supports benefit to very low levels. It says safety concerns such as hemorrhagic stroke, cognitive decline (EBBINGHAUS) and hormone disruption are unsupported, while fewer than one in four high-risk patients reach target.
